Reactive Oxygen Comes of Age : Mechanism-Based Therapy of Diabetic End-Organ Damage
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved..
Reactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Trends in endocrinology and metabolism: TEM - 30(2019), 5 vom: 07. Mai, Seite 312-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elbatreek, Mahmoud H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antioxidants |
|---|
| Anmerkungen: |
Date Completed 27.07.2020 Date Revised 27.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tem.2019.02.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295504412 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295504412 | ||
| 003 | DE-627 | ||
| 005 | 20231225083812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tem.2019.02.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0984.xml |
| 035 | |a (DE-627)NLM295504412 | ||
| 035 | |a (NLM)30928357 | ||
| 035 | |a (PII)S1043-2760(19)30039-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elbatreek, Mahmoud H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reactive Oxygen Comes of Age |b Mechanism-Based Therapy of Diabetic End-Organ Damage |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2020 | ||
| 500 | |a Date Revised 27.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Reactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a NADPH oxidases | |
| 650 | 4 | |a NRF2 | |
| 650 | 4 | |a ROS | |
| 650 | 4 | |a mechanism-based therapies | |
| 650 | 4 | |a network pharmacology | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 700 | 1 | |a Pachado, Mayra P |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadrado, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Jandeleit-Dahm, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Harald H H W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in endocrinology and metabolism: TEM |d 1989 |g 30(2019), 5 vom: 07. Mai, Seite 312-327 |w (DE-627)NLM102549273 |x 1879-3061 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2019 |g number:5 |g day:07 |g month:05 |g pages:312-327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tem.2019.02.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2019 |e 5 |b 07 |c 05 |h 312-327 | ||